8-K: Oramed Pharmaceuticals Restructures Scilex Agreements to Secure Royalty Rights and Gloperba License

Oramed Pharmaceuticals amends agreements with Scilex, acquiring royalty rights on Gloperba and Elyxyb and securing a worldwide license for Gloperba outside the U.S.

Summary

• Oramed Pharmaceuticals Inc. has entered into several agreements with Scilex Pharmaceuticals Inc. and Scilex Holding Company to restructure existing arrangements and secure new rights.
• Oramed, along with other investors, will receive 4% of Scilex's net sales worldwide for Gloperba and Elyxyb, with Oramed receiving 50% of this royalty.
• This agreement involves the sale of purchased receivables related to these royalties to Oramed and other purchasers.
• Oramed has also secured a worldwide exclusive license (excluding the U.S.) for Gloperba, granting them rights to develop, manufacture, and commercialize the product outside the U.S.
• Scilex granted RoyaltyVest Ltd, in which Oramed has a 50% share, the Gloperba license.
• Oramed will also act as the exclusive distributor of Gloperba in the United States during the license term.
• The agreements include amendments to a previous purchase and sale agreement, a security agreement, and a subordination agreement to prioritize the new royalty rights.
• The term of the Gloperba license agreement continues until the expiration of the last licensed patent.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. Oramed secures new revenue streams and commercial opportunities, but the success depends on external factors and execution.

Positives

• Oramed gains a new revenue stream through royalty rights on Gloperba and Elyxyb.
• The exclusive Gloperba license provides Oramed with significant commercial opportunities outside the U.S.
• Oramed secures distribution rights for Gloperba in the U.S.
• The restructuring prioritizes Oramed's royalty rights through security and subordination agreements.

Negatives

• Oramed's revenue from the Gloperba license is dependent on the success of RoyaltyVest Ltd.
• The royalty purchase agreement terminates six months following receipt by the RPA Purchasers of all payments of the Purchased Receivables to which each RPA Purchaser is entitled during the Payment Term.

Risks

• The success of the royalty and license agreements depends on Scilex's ability to generate sales of Gloperba and Elyxyb.
• Regulatory or manufacturing issues with Gloperba could impact Oramed's revenue from the license agreement.
• Potential disputes with Scilex over the interpretation or enforcement of the agreements could arise.
• The agreements are subject to standard risks associated with pharmaceutical development and commercialization.

Future Outlook

Oramed anticipates generating revenue from royalty payments and Gloperba sales outside the U.S. The success depends on Scilex's sales performance and RoyaltyVest's ability to commercialize Gloperba effectively.

Industry Context

This announcement reflects a trend in the pharmaceutical industry where companies restructure agreements to optimize asset utilization and secure revenue streams from promising drug candidates. Oramed's focus on Gloperba aligns with the growing market for specialized pharmaceutical products.

Comparison to Industry Standards

• Royalty agreements in the pharmaceutical industry typically range from single-digit to low double-digit percentages of net sales. Oramed's 50% share of the 4% royalty is within the lower end of this range.
• Exclusive licensing agreements are common for pharmaceutical products, allowing companies to focus on specific geographic markets or therapeutic areas. Oramed's exclusive license for Gloperba outside the U.S. is a standard arrangement.
• Comparable companies that engage in similar royalty and licensing agreements include Ligand Pharmaceuticals, Royalty Pharma, and XOMA Corporation. These companies specialize in acquiring and managing royalty streams from pharmaceutical products.

Stakeholder Impact

• Shareholders: Potential for increased revenue and profitability for Oramed.
• Employees: Possible new roles and responsibilities related to Gloperba commercialization.
• Customers: Continued access to Gloperba and Elyxyb.
• Suppliers: Potential for increased demand for Gloperba and Elyxyb.
• Creditors: Improved financial stability for Oramed.

Next Steps

• Oramed to work with Scilex to ensure smooth transition of Gloperba commercialization outside the U.S.
• RoyaltyVest Ltd. to develop and execute a commercialization plan for Gloperba outside the U.S.
• Oramed to monitor Scilex's sales of Gloperba and Elyxyb to ensure accurate royalty payments.

Key Dates